|Table of Contents|

Clinical efficacy of bevacizumab sequential combined with mFOLFOX or FOLFIRI in the treatment metastatic colorectal cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 05
Page:
880-885
Research Field:
Publishing date:

Info

Title:
Clinical efficacy of bevacizumab sequential combined with mFOLFOX or FOLFIRI in the treatment metastatic colorectal cancer
Author(s):
TIAN Yuan; WANG Haiyan; XU Zeyu
Department of Medical Oncology,the Affiliated Hospital of Xuzhou Medical University,Jiangsu Xuzhou 221002,China.
Keywords:
metastatic colorectal cancer; bevacizumab; left/right colon cancer; BRAF gene
PACS:
R735.3+5
DOI:
10.3969/j.issn.1672-4992.2023.05.018
Abstract:
Objective：To observe the efficacy of sequential bevacizumab combined with mFOLFOX or FOLFIRI in the first/second line treatment of advanced metastatic colorectal cancer.Methods:101 patients with mCRC treated by sequential bevacizumab combined with mFOLFOX or FOLFIRI in our hospital from January 2017 to June 2021 were analyzed retrospectively with their objective response rate(ORR),disease control rate(DCR),progression-free survival(PFS),and overall survival(OS).Results:In pre mFOLFOX group(n=52),the ORR of first line was 44.2% and the DCR was 86.5%,the ORR of second line was 24% and the DCR was 60%.In pre FOLFIRI group(n=49),the ORR of first line was 42.9% and the DCR was 81.6%,and the ORR of second line was 29.2% and the DCR was 62.5%.Kaplan-Meier analysis showed that the two group had no significant effect on PFS and OS.The results of Cox multifactor analysis show that the two groups have statistical significance in the tumor principle(left,right colon),and BRAF gene status.The hematological adverse reactions in the two groups were mainly white blood cells,and platelet reduction,anemia,non-hematological adverse reactions were gastrointestinal response and peripheral sensory neuropathy,and bevacizumab related adverse reactions were mainly hypertension,proteinuria and thrombosis.The incidence of adverse events in the two groups respectively was 29％,24％ and 11％.There was no statistical significant difference between the two groups.Conclusion:Bevacizumab sequential combined with chemotherapy for patients with metastatic colorectal cancer is obvious.Adverse reactions are controllable.It has a tendency to benefit OS of left colon cancer and BRAF gene wild type.

References:

[1]中华人民共和国国家卫生健康委员会医政医管局,中华医学会肿瘤学分会.中国结直肠癌诊疗规范（2020年版）［J］.中国实用外科杂志,2020,40(06):601-625. Hospital Authority of National Health Commission of the People's Republic of China,Chinese Society of Oncology,Chinese Medical Association.Chinese protocol of diagnosis and treatment of colorectal cancer(2020 edition) ［J］.Chinese Journal of Practical Surgery,2020,40(06):601-625.
[2] BATTAGLIN F,SCHIRRIPA M,BUGGIN F,et al.The PANDA study:a randomized phase II study of first-line FOLFOX plus panitumumab versus 5-FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients ［J］.BMC Cancer,2018,18(1):98.
[3] YAMAZAKI K,NAGASE M,TAMAGAWA H,et al.Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer(WJOG4407G) ［J］.Annals of Oncology,2016,27(8):1539-1546.
[4] 韩建雄,骆成俊,杨波,等.贝伐珠单抗联合不同化疗方案治疗转移性结直肠癌的疗效及安全性分析 ［J］.解放军医药杂志,2019,31(10):27-30. HAN Jianxiong,LUO Chengjun,YANG Bo,et al.Efficacy and safety of bevacizumab combined with different chemotherapy regimens in treatment of patients with metastatic colorectal cancer［J］.Medical & Pharmaceutical Journal of Chinese People's Liberation Army,2019,31(10):27-30.
[5] OGATA T,SATAKE H,OGATA M,et al.Safety and effectiveness of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer:A multicenter retrospective study ［J］.Oncotarget,2019,10(10):1070-1084.
[6] 秦叔逵,邓艳红,毕锋,等.贝伐珠单抗联合含氟尿嘧啶类化疗方案治疗晚期转移性结直肠癌的前瞻性、非干预性、全国多中心临床研究(REACT) ［J］.临床肿瘤学杂志,2016,21(10):865-873. QIN Shukui,DENG Yanhong,BI Feng,et al.Efficacy and safety of bevacizumab in combination with fluoropyrimidine-based chemotherapy for the treatment of advanced metastatic colorectal cancer:a prospective，non-intervention and post-marketing multicenter clinical study(REACT)［J］.Chinese Clinical Oncology,2016,21(10):865-873.
[7] 邓文静,余更生,刘爱,等.贝伐珠单抗联合mFOLFOX6治疗转移性结直肠癌的临床疗效及左右半结肠癌的疗效差异［J］.现代肿瘤医学,2020,28(05):779-783. DENG Wenjing,YU Gengsheng,LIU Ai,et al.The clinical efficacy of bevacizumab combined with mFOLFOX6 in the treatment of metastatic colorectal cancer and the difference between left and right colon cancer［J］.Modern Oncology,2020,28(05):779-783.
[8] STINTZING S,WIRAPATI P,LENZ HJ,et al.Consensus molecular subgroups(CMS) of colorectal cancer(CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3(AIO KRK-0306) trial ［J］.Annals of Oncology,2019,30(11):1796-1803.
[9] 李晓辉,李丁伟,初黎明,等.FOLFOX方案与FOLFIRI方案治疗晚期结直肠癌的效果分析 ［J］.中国肛肠病杂志,2019,39(12):5-7. LI XH,LI W,CHU LM,et al.Analysis on the effect of late colorectal carcinoma treated with FOLFOX scheme and with FOLFIRI scheme［J］.Chinese Journal of Coloproctology,2019,39(12):5-7.
[10]曹云,李烜,史碧霄.FOLFOX4方案治疗晚期左、右半结肠癌疗效的回顾性分析［J］.现代肿瘤医学,2018,26(19):3090-3094. CAO Yun,LI Xuan,SHI Bixiao.Retrospective analysis of the clinical observation of FOLFOX4 regimen for advanced left and right colon cancer［J］.Modern Oncology,2018,26(19):3090-3094.
[11] 王慧,任建琳,张功,等.不同部位结直肠癌术后患者生存预后差异分析 ［J］.疑难病杂志,2021,20(05):440-445. WANG Hui,REN Jianlin,ZHANG Gong,et al.Analysis of differences in survival and prognosis of postoperative patients with colorectal cancer in different locations［J］.Difficult and Complicated Cases,2021,20(05):440-445.
[12] AFRASANIE VA,MARINCA MV,ALEXA-STRATULAT T,et al.KRAS,NRAS,BRAF,HER2 and microsatellite instability in metastatic colorectal cancer -practical implications for the clinician ［J］.Radiology and Oncology,2019,53(3):265-274.
[13] SHAHJEHAN F,KAMATHAM S,CHANDRASEKHARAN C,et al.Binimetinib,encorafenib and cetuximab(BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer ［J］.Drugs of Today(Barcelona,Spain:1998),2019,55(11):683-693.
[14] 许婷,王晰程,李健,等.BRAF(V600E)突变型晚期结直肠癌靶向治疗的临床分析 ［J］.临床肿瘤学杂志,2020,25(07):613-618. XU Ting,WANG Xicheng,LI Jian,et al.Efficacy and safety of targeted therapy in BRAF V600E mutated metastatic colorectal cancer［J］.Chinese Clinical Oncology,2020,25(07):613-618.
[15] HEGEWISCH-BECKER S,NOPEL-DUNNEBACKE S,HINKE A,et al.Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab:Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial ［J］.European Journal of Cancer,2018,101(10):5-13.
[16] CHIHIRO K,KEIJI K,TADAMICHI D,et al.Multicenter phase II clinical study of the efficiency and safety of capecitabine plus intermittent oxaliplatin with bevacizumab as first-line therapy in patients with metastatic colorectal cancer(VOICE trial) ［J］.International Journal of Colorectal Disease,2021,30(11):17-80.
[17] 施志杰.贝伐珠单抗联合FOLFOX治疗转移性结直肠癌的有效性与安全性 ［J］.临床医学,2021,41(07):88-90. SHI Zhijie.Effectiveness and safety of beacizumab combined with FOLFOX to treat metastatic colorectal cancer［J］.Clinical Medicine,2021,41(07):88-90.

Memo

Memo:
-
Last Update: 2023-01-31